Program
fenebrutinib
Also written as “GDC-0853”, “Fenebrutinib” and “Simvastatin and GDC-0853”.
Its studies are mostly in Multiple Sclerosis · Lupus Erythematosus, Systemic · Urticaria · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 186 open or running | phase 3since Sep 4, 2020 | Nov 18, 2013 | Jun 8, 2027phase 2 · NCT07161258 |
- Named in Hoffmann-La Roche’s own pipeline as
RG7845 fenebrutinib
, phase 4, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 18, 2013.
- Sep 14, 2016Phase 2 study in Lupus Erythematosus, SystemicNCT02908100 · 260 enrolled · United States, Argentina, Brazil and more
- Nov 29, 2016Phase 2 study in Arthritis, RheumatoidNCT02983227 · 496 enrolled · United States, Argentina, Brazil and more
- Apr 28, 2017Phase 2 study in UrticariaNCT03137069 · 134 enrolled · United States, Canada, Germany
- May 4, 2017Phase 1 study in Healthy ParticipantsNCT03174041 · 63 enrolled · United States
- Jun 14, 2017Phase 1 study in Healthy VolunteerNCT03188783 · 32 enrolled · United States
- Sep 19, 2017Phase 1 study in Healthy VolunteersNCT03290703 · 63 enrolled · United Kingdom
- Jan 15, 2018Phase 2 study in Lupus Erythematosus, SystemicNCT03407482 · 160 enrolled · United States, Argentina, Brazil and more
- Jul 13, 2018Phase 1 study in Healthy ParticipantsNCT03596632 · 8 enrolled · United States
- Oct 1, 2018Phase 2 study in UrticariaNCT03693625 · 31 enrolled · United States
- Sep 4, 2020Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT04544449 · 985 enrolled · United States, Argentina, Australia and more
- Oct 8, 20202 phase 3 studies in Relapsing Multiple SclerosisNCT04586023, NCT04586010
- Oct 29, 2021Phase 2 study in Relapsing Multiple SclerosisNCT05119569 · 109 enrolled · United States, Bosnia and Herzegovina, Croatia and more
- Aug 20, 2025Phase 2 study in Relapsing Multiple SclerosisNCT07161258 · 12 planned · Argentina, Brazil, Mexico and more
- Nov 10, 2026Phase 3 study in Multiple SclerosisNCT07937852 · 1,800 planned
Ahead
- Jun 8, 2027Primary completion: phase 2 study in Relapsing Multiple SclerosisNCT07161258
- Nov 30, 2029Primary completion: phase 3 study in Multiple SclerosisNCT07937852
TargetBeta
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-m…”NCIt, read by Claude
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07937852Multiple Sclerosis | 3 | Not yet recruiting | Nov 30, 2029 | 1,800 |
| NCT07161258Relapsing Multiple Sclerosis · Argentina, Brazil, Mexico and more | 2 | Recruiting | Jun 8, 2027 | 12 |
| NCT05119569Relapsing Multiple Sclerosis · United States, Bosnia and Herzegovina, Croatia and more | 2 | Active, not recruiting | Mar 29, 2023 | 109 |
| NCT04586023Relapsing Multiple Sclerosis · United States, Austria, Brazil and more | 3 | Active, not recruiting | Sep 5, 2025 | 751 |
| NCT04586010Relapsing Multiple Sclerosis · United States, Argentina, China and more | 3 | Active, not recruiting | Jan 27, 2026 | 746 |
| NCT04544449Multiple Sclerosis, Chronic Progressive · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 17, 2025 | 985 |
| NCT03693625Urticaria · United States | 2 | Terminated | Oct 23, 2019 | 31 |
| NCT03596632Healthy Participants · United States | 1 | Completed | Aug 23, 2018 | 8 |
| NCT03407482Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Terminated | Nov 20, 2019 | 160 |
| NCT03290703Healthy Volunteers · United Kingdom | 1 | Completed | Oct 25, 2018 | 63 |
| NCT03188783Healthy Volunteer · United States | 1 | Completed | Aug 9, 2017 | 32 |
| NCT03174041Healthy Participants · United States | 1 | Completed | Jun 23, 2017 | 63 |
| NCT03137069Urticaria · United States, Canada, Germany | 2 | Completed | Sep 27, 2019 | 134 |
| NCT02983227Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 2 | Completed | Jul 17, 2019 | 496 |
| NCT02908100Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Completed | May 28, 2019 | 260 |
| NCT02833350Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 2 | Completed | Jul 2, 2018 | 578 |
| NCT02699710Healthy Volunteer · United Kingdom | 1 | Completed | May 26, 2016 | 50 |
| NCT01991184Leukemia, Lymphoid · United States, Australia | 1 | Completed | Mar 8, 2022 | 24 |
How it is read
Names in the registry
- “GDC-0853”, 12 entries
- “Fenebrutinib”, 7 entries
- “Simvastatin and GDC-0853”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 5 studies
- Lupus Erythematosus, Systemic, 2 studies
- Urticaria, 2 studies
- Arthritis, Rheumatoid, 2 studies
- Multiple Sclerosis, Chronic Progressive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.